Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells

Currently available SARS-CoV-2 therapeutics are targeted toward moderately to severely ill patients and require intravenous infusions, with limited options for exposed or infected patients with no or mild symptoms. Although vaccines have demonstrated protective efficacy, vaccine hesitancy and logist...

Descripción completa

Detalles Bibliográficos
Autores principales: Goswami, Ria, Russell, Veronica S., Tu, Joshua J., Thomas, Charlene, Hughes, Philip, Kelly, Francine, Langel, Stephanie N., Steppe, Justin, Palmer, Scott M., Haystead, Timothy, Blasi, Maria, Permar, Sallie R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579697/
https://www.ncbi.nlm.nih.gov/pubmed/34786537
http://dx.doi.org/10.1016/j.isci.2021.103412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579697/
https://www.ncbi.nlm.nih.gov/pubmed/34786537
http://dx.doi.org/10.1016/j.isci.2021.103412

Ejemplares similares